2. Academic Validation
  3. Discovery of small-molecule candidates against inflammatory bowel disease

Discovery of small-molecule candidates against inflammatory bowel disease

  • Eur J Med Chem. 2020 Jan 1:185:111805. doi: 10.1016/j.ejmech.2019.111805.
Renren Bai 1,  Xiaokang Jie 2,  Chuansheng Yao 2,  Yuanyuan Xie 3
Affiliations

Affiliations

  • 1 College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, PR China. Electronic address: renrenbai@zjut.edu.cn.
  • 2 College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, PR China.
  • 3 College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, PR China. Electronic address: xyycz@zjut.edu.cn.
PMID: 31703817 DOI: 10.1016/j.ejmech.2019.111805
Abstract

Inflammatory bowel disease (IBD) is a chronic and recurrent inflammatory disease in the gastrointestinal tract emerged as a public health challenge worldwide. IBD exhibits a relapsing and remitting course results in negative impacts on both physical and psychological health of IBD patients. Great efforts have been made during the past few years, but relatively limited drugs are currently available for the management of IBD. Clinically, there is a strong demand for new drugs for the treatment of IBD with better efficacy and lower side effects. This review focuses on the drug discovery process of the anti-IBD agents, aiming to introduce the general characteristics of IBD, as well as systematically summarize the recent advances in the discovery of small-molecule candidates and Natural Products with promising in vivo potential for the treatment of IBD.

Keywords

Crohn’s disease; Inflammatory bowel disease; Natural products; Small molecules; Ulcerative colitis.

Figures